REPL Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Replimune Group's net margin of -49.65%. Replimune Group's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Replimune Group has a consensus price target of $22.25, signalling upside risk potential of 76.17%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Replimune Group has higher upside potential than NovaBay Pharmaceuticals, analysts believe Replimune Group is more attractive than NovaBay Pharmaceuticals.

Replimune Group has a beta of 0.614, which suggesting that the stock is 38.61% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Replimune Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Replimune Group quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Replimune Group's net income of -$74.1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Replimune Group's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nanoviricides has a net margin of -- compared to Replimune Group's net margin of --. Replimune Group's return on equity of -- beat Nanoviricides's return on equity of --.

Replimune Group has a consensus price target of $22.25, signalling upside risk potential of 76.17%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 306.25%. Given that Nanoviricides has higher upside potential than Replimune Group, analysts believe Nanoviricides is more attractive than Replimune Group.

Replimune Group has a beta of 0.614, which suggesting that the stock is 38.61% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

Replimune Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Replimune Group quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Replimune Group's net income of -$74.1M is lower than Nanoviricides's net income of -$2.2M. Notably, Replimune Group's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Replimune Group's net margin of --. Replimune Group's return on equity of -- beat Oragenics's return on equity of --.

Replimune Group has a consensus price target of $22.25, signalling upside risk potential of 76.17%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Replimune Group, analysts believe Oragenics is more attractive than Replimune Group.

Replimune Group has a beta of 0.614, which suggesting that the stock is 38.61% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Replimune Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Replimune Group quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Replimune Group's net income of -$74.1M is lower than Oragenics's net income of -$2.2M. Notably, Replimune Group's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group is -- versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Replimune Group's net margin of --. Replimune Group's return on equity of -- beat Theriva Biologics's return on equity of --.

Replimune Group has a consensus price target of $22.25, signalling upside risk potential of 76.17%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Replimune Group, analysts believe Theriva Biologics is more attractive than Replimune Group.

Replimune Group has a beta of 0.614, which suggesting that the stock is 38.61% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Replimune Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Replimune Group quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Replimune Group's net income of -$74.1M is lower than Theriva Biologics's net income of -$4.3M. Notably, Replimune Group's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.